Aspen Oss’ response to COVID-19

On a worldwide basis more and more people are being hospitalized due to COVID-19. Due to this we have seen a strong increase in demand for some of our APIs. Please be assured that we are fully aware of the importance of these APIs becoming available to the market so that patients can be helped. Our efforts are focused on insuring meeting the requirements of our current customers and rapidly addressing the needs of new customers.

In case of any specific questions, we kindly request you to contact your regular sales person or to reach out via our general email address api@nl.aspenpharma.com  We will then come back to you soonest with more information regarding your question.

Aspen Pharma’s response to COVID-19

Aspen Oss is part of the South African Aspen Pharma Group, which is a global specialty and branded pharmaceutical company dating back more than 160 years.

The Group has a business presence in 55 countries with approximately 10 000 employees. We manufacture an extensive portfolio of products with specific focus on Sterile Focus Brands comprising anaesthetics and thrombosis as well as Regional Brands that include leading domestic brands in the Sub-Saharan Africa, Australasia and Latin American territories.

In case of questions regarding the availability of Aspen’s finished dosage forms, we kindly request you to contact www.aspenpharma.com  or one of their local sales offices.  For more information we also welcome you to visit this link : https://www.aspenpharma.com/our-response-to-covid-19/